Acura Pharmaceuticals, Inc. is a drug delivery company, which engages in the research, development, and commercialization of technologies and products intended to address safe use of medications. The company is headquartered in Palatine, Illinois. The company went IPO on 2000-09-12. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
Follow-Up Questions
¿Quién es el CEO de Acura Pharmaceuticals Inc?
Mr. Robert Jones es el President de Acura Pharmaceuticals Inc, se unió a la empresa desde 2008.
¿Qué tal es el rendimiento del precio de la acción ACUR?
El precio actual de ACUR es de $0.0002, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Acura Pharmaceuticals Inc?
Acura Pharmaceuticals Inc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Acura Pharmaceuticals Inc?
La capitalización bursátil actual de Acura Pharmaceuticals Inc es $13269.999800000001